Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C

Hepatology Research

Volumn 45, Issue 13, 2015, Pages 1360-1362

  Ueda, Yoshihide ^a   Kaido, Toshimi ^a   Hatano, Etsuro ^a   Ohtsuru, Shigeru ^a   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Asunaprevir; Cholestatic hepatitis; Daclatasvir; Hepatitis C; Liver transplantation; Tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; BILIRUBIN; DACLATASVIR; GAMMA GLUTAMYLTRANSFERASE; INTERFERON; PEGINTERFERON; PIPERACILLIN; RIBAVIRIN; TACROLIMUS; TAZOBACTAM; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BACTERIAL INFECTION; CASE REPORT; CATHETER INFECTION; CATHETER RELATED BACTEREMIA; CHOLESTASIS; CHOLESTATIC HEPATITIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAFT RECIPIENT; HEPATITIS C VIRUS; HEPATOCYTE BALLOONING DEGENERATION; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; PERIPHERAL VENOUS CATHETER; PERISINUSOIDAL FIBROSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SERRATIA MARCESCENS; SEVERE CHOLESTATIC HEPATITIS C; SPOTTY ACIDOPHILIC BODY; TREATMENT DURATION;

EID: 84983160179     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12509     Document Type: Article

References (7)

1. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010 Nov 16: 1228-35.
2. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012 Aug 26: 531-48.
3. Ong JP, Younossi ZM, Gramlich T et al. Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation 2001 May 27 71: 1486-7.
4. Fontana RJ, Hughes EA, Bifano M et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013 Jun 13: 1601-5.
5. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014 Jun 59: 2083-91.
6. Kugelmas M, Osgood MJ, Trotter JF et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003 Nov 9: 1159-65.
7. Ueda Y, Kaido T, Uemoto S. Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation. Transpl Int 2015 Feb 28: 251-2.